STORMSHIELD
26.2.2016 15:15:53 CET | Business Wire | Press release
Stormshield, a key player on the cyber security market, is announcing its participation in the RSA 2016 conference taking place in San Francisco from 29 February to 4 March next. During the event, Stormshield will give a preview of Stormshield Data Security for Cloud & Mobility: its cloud-based data encryption solution.
Stormshield Data Security for Cloud & Mobility lets businesses and organisations use all the power and agility of cloud-based collaborative applications like Microsoft Office365 or Dropbox while staying in control of outsourced data privacy. Employees can easily collaborate with internal and external users across any platform (Windows, iOS, Android, etc.) by sharing encrypted data via their applications. The protection scheme implemented is totally platform-independent.
Stormshield will also introduce its “Multi-layer Collaborative Security” approach, a holistic model based on active collaboration between security engines built into the different solutions. This concept embodies the future of deep information system defence and delivers new-generation protection against the increasingly sophisticated threats that easily bypass traditional security technologies.
This year will also be an opportunity to unveil Stormshield Network Security’s “clean and pass” technology, which enhances the user experience by removing malicious scripts in website code on the fly, without blocking access to the sites.
In addition, visitors will be able to attend presentations on Stormshield Endpoint Security and its proactive behavioural analysis technology dedicated to protecting workstations and servers against 0-day threats and ransomware.
If you’d like to make an appointment with Matthieu Bonenfant, Product
Marketing Director, please contact us:
Caroline Pain–
cpain@meiji-communication.com
+ 33 6.50.42.07.67
Sandra Labérenne –
slaberenne@meiji-communication.com
– +33 6.43.19.13.88
About Stormshield –
www.stormshield.eu
Stormshield
offers innovative end-to-end security solutions worldwide to protect
networks (Stormshield Network Security), workstations (Stormshield
Endpoint Security) and data (Stormshield Data Security). These
next-generation trusted solutions, certified at the highest level in
Europe (EU RESTRICTED, NATO and ANSSI EAL4+), ensure the protection of
strategic information and are deployed through a partner network of
distributors, integrators and operators in businesses of all sizes,
government institutions and defense organizations worldwide.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160226005283/en/
Contact:
Press contact
Sandra Laberenne
slaberenne@meiji-communication.com
or
Caroline
Pain
cpain@meiji-communication.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 13:44:00 CET | Press release
CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.
Nominations Open for Sixth Edition of Aster Guardians Global Nursing Award 2027 Worth USD 250,000 Prize9.11.2026 13:35:00 CET | Press release
Aster DM Healthcare has announced the launch of the sixth edition of the Aster Guardians Global Nursing Award, inviting registered nurses worldwide to showcase their contributions to healthcare and compete for a prize of USD 250,000. The award recognises nurses whose work advances patient care, strengthens healthcare systems, drives innovation and transforms communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109180902/en/ Aster Guardians Global Nursing Award - One nurse will win the trophy and the prize of USD 250,000 (Photo: AETOSWire) Open to registered nurses worldwide, the award recognises contributions across five areas: Patient Care, Nursing Education, Social and Community Service, Research and Innovation, and Nursing Leadership and Administration. Applicants can share their professional journeys through case-study questions, in multiple languages at www.asterguardians.com until December 31, 2026. The 2026
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 12:45:00 CET | Press release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 12:45:00 CET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press release
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom